Want to see IN:WOCKPHARMA full AI Analyst Report?
WOCKPHARMA Stock Chart & Stats
₹1405.55
-₹25.55(-1.72%)
At close: 4:00 PM EST
₹1405.55
-₹25.55(-1.72%)
Day’s Range― - ―
52-Week Range₹1,086.80 - ₹2,420.00
Previous CloseN/A
Volume236.67K
Average Volume (3M)80.75K
Market Cap
₹317.02B
Enterprise Value₹210.41K
Total Cash (Recent Filing)₹6.80B
Total Debt (Recent Filing)₹0.00
Price to Earnings (P/E)83.0
Beta1.23
Next Earnings
Nov 09, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield1.27%
Share Statistics
EPS (TTM)25.16
Shares Outstanding162,485,570
10 Day Avg. Volume109,688
30 Day Avg. Volume80,753
Financial Highlights & Ratios
PEG Ratio-0.17
Price to Book (P/B)3.86
Price to Sales (P/S)5.66
P/FCF Ratio298.24
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Revenue Recovery And ProfitabilityImproved revenue growth and a return to net profit indicate that the business is recovering from its prior downturn. Sustaining this trajectory could strengthen operating scale, support reinvestment, and improve resilience across its pharmaceutical portfolio.
Stronger Balance SheetStable debt alongside a larger equity base provides greater balance-sheet cushioning and financial flexibility. This can help Wockhardt fund development, manufacturing, and regulatory needs while reducing the impact of future earnings volatility.
Operating Cash Flow ReboundThe return to positive operating cash flow suggests improved conversion of pharmaceutical sales into internally generated funds. If maintained, this can reduce reliance on external financing and support ongoing product development and manufacturing operations.
Bears Say
Inconsistent ProfitabilitySeveral years of losses and volatile operating profit indicate that the recovery has not yet demonstrated durable earnings stability. Continued margin swings could constrain investment capacity, weaken confidence in forecasts, and expose the business to execution risk.
Uneven Cash ConversionModest and historically volatile free cash flow suggests that reported earnings do not consistently convert into cash. Working-capital needs or reinvestment may continue absorbing funds, limiting debt reduction, shareholder returns, and business flexibility.
Regulatory And Generic Competition ExposureWockhardt’s access to higher-value markets depends on maintaining regulatory compliance and approvals, while generic competition can pressure prices and margins. These structural dependencies may make growth and profitability uneven across products and geographies.
Wockhardt Limited News
WOCKPHARMA FAQ
What was Wockhardt Limited’s price range in the past 12 months?
Wockhardt Limited lowest stock price was ₹1086.80 and its highest was ₹2420.00 in the past 12 months.
What is Wockhardt Limited’s market cap?
Wockhardt Limited’s market cap is ₹317.02B.
When is Wockhardt Limited’s upcoming earnings report date?
Wockhardt Limited’s upcoming earnings report date is Nov 09, 2026 which is in 64 days.
How were Wockhardt Limited’s earnings last quarter?
Wockhardt Limited released its earnings results on Aug 10, 2026. The company reported ₹6.523 earnings per share for the quarter.
Is Wockhardt Limited overvalued?
According to Wall Street analysts Wockhardt Limited’s price is currently Overvalued.
Does Wockhardt Limited pay dividends?
Wockhardt Limited pays a Notavailable dividend of ₹9.218 which represents an annual dividend yield of 1.27%. See more information on Wockhardt Limited dividends here
What is Wockhardt Limited’s EPS estimate?
Wockhardt Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Wockhardt Limited have?
Wockhardt Limited has 162,485,570 shares outstanding.
What happened to Wockhardt Limited’s price movement after its last earnings report?
Wockhardt Limited reported an EPS of ₹6.523 in its last earnings report. Following the earnings report the stock price went down -4.36%.
Which hedge fund is a major shareholder of Wockhardt Limited?
Currently, no hedge funds are holding shares in IN:WOCKPHARMA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Wockhardt Limited
Wockhardt Limited, together with its subsidiaries, operates as a pharmaceutical and biotech company, in India, the United States, the United Kingdom, Switzerland, Ireland, Russia, Europe, and internationally. It manufactures and trades pharmaceuticals, medicinal chemical, and botanical products, as well as chemicals and chemical products. The company also develops its flagship antibiotic, ZAYNICH zidebactam/cefepime, a novel beta lactam enhancer mechanism for the treatment of sepsis and hospital/ventilator associated pneumonia; FOVISCU, an antibiotic for gram-negative infections; MIQNAF nafithromycin, which targets azithromycin-resistant community respiratory pathogens; and ODRATE, a once-daily combination of ertapenem and zidebactam for resistant gram-negative infections through outpatient parenteral antimicrobial therapy. In addition, it develops and commercializes insulin analogs, glucagon-like peptide-1 agonists, and novel combination drug products; Biovac-B, a recombinant hepatitis-B vaccine; Wepox, a recombinant human erythropoietin; Wosulin, a recombinant human insulin; and Glaritus, a recombinant insulin glargine. Further, the company offers delivery devices for insulin, including Dispopen disposable pen and Mypen reusable pen. Wockhardt Limited was founded in 1967 and is headquartered in Mumbai, India.
Technical Analysis
Ajanta Pharma Limited
―
Alkem Laboratories Ltd.
―
Emcure Pharmaceuticals Limited
―
Glenmark Pharmaceuticals Limited
―
IPCA Laboratories Limited
―